Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance

Vaccine
A BallochM L K Tang

Abstract

Quantitation of specific IgG to polysaccharides (serotypes) of Streptococcus pneumoniae provides the basis for evaluating vaccine efficacy. Different enzyme-linked immunosorbent assay (ELISA) methods are used internationally, making comparisons between laboratories difficult. We undertook an inter-laboratory comparison between two international laboratories performing serotype-specific IgG ELISAs using a panel of well-characterized serum samples: the Murdoch Childrens Research Institute Pneumococcal Laboratory (Melbourne, Australia) and the Vaccine Immunology Laboratory, National Public Health Institute (Helsinki, Finland). While good agreement was found for the inter-laboratory comparison for most serotypes, differences in ELISA methodology influenced specific IgG measurement. Therefore, use of the World Health Organization (WHO)-based ELISA methods for measurement of serotype-specific IgG is reliable, accurate and provides consistent results between international laboratories.

References

Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A BruynR van Furth
Jun 1, 1992·The Journal of Infectious Diseases·K E Stein
May 11, 1995·The New England Journal of Medicine·E I TuomanenH R Masure
Apr 16, 1998·The Journal of Infectious Diseases·A M StackR A Saladino
Sep 2, 1999·Lancet·K Mulholland
Mar 18, 2000·Infection and Immunity·C E Frasch, N F Concepcion
May 9, 2000·Clinical and Diagnostic Laboratory Immunology·A SoininenH Käyhty
Apr 23, 2003·Vaccine·Lucia H LeeCarolyn D Deal
Jul 11, 2003·Clinical and Diagnostic Laboratory Immunology·Catherine M WernetteMoon H Nahm
Sep 11, 2003·Clinical and Diagnostic Laboratory Immunology·Raymond E BiaginiDavid N Weissman
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Richard MalleyMarc Lipsitch
Oct 15, 1957·Proceedings of the National Academy of Sciences of the United States of America·M Heidelberger
Apr 5, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eugene V MillarMathuram Santosham
Jun 20, 2007·Infection and Immunity·In Ho ParkMoon H Nahm
Dec 28, 2007·Vaccine·Africa González-FernándezCarmen Fernández
Sep 20, 2008·PLoS Pathogens·Ying-Jie LuRichard Malley

❮ Previous
Next ❯

Citations

Mar 1, 2012·Analytical and Bioanalytical Chemistry·Mark SykesBhavna Parmar
Feb 7, 2012·The Journal of Allergy and Clinical Immunology·Paul V LicciardiMimi L K Tang
Jun 30, 2010·The Journal of Allergy and Clinical Immunology·Anne BallochMimi L K Tang
May 15, 2015·Human Vaccines & Immunotherapeutics·Nicola Principi, Susanna Esposito
Aug 8, 2014·The Pediatric Infectious Disease Journal·Nigel W CrawfordJim P Buttery
Mar 8, 2018·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Claire DendleWilliam R Mulley
May 3, 2011·Nature Reviews. Drug Discovery·Paul V LicciardiMimi L K Tang
Sep 6, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·William S PomatUNKNOWN 10v13v PCV Trial Team

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.